Capricor Therapeutics 株価情報 (NASDAQ: CAPR)

Capricor Therapeutics (NASDAQ:CAPR) 株価情報

Capricor Therapeutics

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday.
Shares of Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) fell sharply in today's pre-market trading <a href="https://www.benzinga.com/quote/HOOD">amid decline in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices</a>.
Bitcoin prices fell below the $82,000 mark this morning.
Robinhood shares dipped 6% to $39.40 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) shares dipped 37.7% to $7.00 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) declined 19.9% to $9.21 in pre-market trading. The company, last week, reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Marblegate Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GATE#NASDAQ">GATE</a>) shares tumbled 19% to $32.40 in pre-market trading.</li>
<li>Arhaus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) fell 18.3% to $7.00 in pre-market trading after tumbling over 8% on Friday.</li>
<li>NeOnc Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares declined 17.7% to $14.00 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares dipped 16.7% to $2.50 in pre-market trading.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) declined 14.3% to $15.40 in today's pre-market trading.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) shares fell 11.7% to $1.29 in pre-market trading. KULR Technology Group, on Thursday, announced fourth-quarter earnings, surpassing revenue expectations.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) declined 9.2% to $7.40 in pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) shares fell 8.1% to $14.40 in pre-market trading after gaining 7% on Friday.</li>
<li>Innovative Industrial Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) fell 5.7% to $58.30 in pre-market trading. Innovative Industrial Properties reported defaults by Tenants.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44554966/pvh-progress-software-and-3-stocks-to-watch-heading-into-monday">PVH, Progress Software And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>
Photo: Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

ARHS

BASE

CAPR

CDNA

GATE

HOOD

IIPR

INNV

KULR

NTHI

RGTI

Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Xos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) rose sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/XOS">reported 2024 results</a>.
The company reported its 2024 revenue surged to $56 million, compared to $44.5 million in 2023. The company delivered 297 units in 2024, up from 283 units in the previous year. Its GAAP gross margins improved from a negative 2.9% in 2023 to a positive 7.1% in 2024.
Xos shares jumped 9% to $3.75 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 75.3% to $0.1402 in pre-market trading after falling over 22% on Friday.</li>
<li>Citius Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) rose 50.4% to $1.00 in pre-market trading.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) rose 50% to $1.20 in pre-market trading after falling around 5% on Friday.</li>
<li>iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>) gained 37.2% to $0.3910 in pre-market trading after dipping more than 17% on Friday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 30.1% to $4.45 in pre-market trading after gaining around 12% on Friday. QuantaSing Group, last week, expanded into pop toys market with strategic acquisition of Letsvan.</li>
<li>Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) rose 19.2% to $0.8701 in pre-market trading after declining 5% on Friday.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) surged 15.5% to $0.1397 in pre-market trading. AIM ImmunoTech, last week, posted upbeat FY 2024 results.</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) gained 7.7% to $17.96 in pre-market after declining 8% on Friday.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 6.3% to $20.99 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares fell 48.3% to $0.0176 in pre-market trading after dipping 23% on Friday.</li>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) fell 37.7% to $7.00 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 19.9% to $9.21 in pre-market trading. The company, last week, reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) declined 19.5% to $7.00 in pre-market trading.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) fell 18.7% to $0.35 in pre-market trading. Enzo Biochem announced plans to voluntarily delist its common stock from the new York Stock Exchange.</li>
<li>Arhaus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) dipped 18.3% to $7.00 in pre-market trading after tumbling over 8% on Friday.</li>
<li>NeOnc Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares dipped 17.7% to $14.00 in pre-market trading.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares tumbled 15.3% to $0.0288 in pre-market trading after falling over 20% on Friday.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) fell 14.3% to $15.40 in today's pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) shares fell 8.1% to $14.40 in pre-market trading after gaining 7% on Friday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/03/44534977/jim-cramer-healthpeak-properties-is-a-reasonable-reit-recommends-buying-this-health-care-stock">Jim Cramer: Healthpeak Properties Is A &#8216;Reasonable&#8217; REIT, Recommends Buying This Health Care Stock</a></li>
</ul>

CTOR

DGLY

HLMN

ICCT

TILE

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Financial giants have made a conspicuous bearish move on Capricor Therapeutics. Our analysis of options history for Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $180,000, and 6 were calls, valued at $340,710.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $30.0 for Capricor Therapeutics over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Capricor Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Capricor Therapeutics's whale activity within a strike price range from $10.0 to $30.0 in the last 30 days. 
<h3>Capricor Therapeutics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743095917_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$0.75</td>
<td>$0.5</td>
<td>$0.75</td>
<td>$12.50</td>
<td>$150.0K</td>
<td>456</td>
<td>2.0K</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.9</td>
<td>$0.75</td>
<td>$0.75</td>
<td>$15.00</td>
<td>$89.2K</td>
<td>4.1K</td>
<td>1.5K</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$0.5</td>
<td>$0.3</td>
<td>$0.4</td>
<td>$15.00</td>
<td>$80.0K</td>
<td>3.4K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$1.0</td>
<td>$0.85</td>
<td>$0.75</td>
<td>$15.00</td>
<td>$51.7K</td>
<td>4.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$5.0</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$15.00</td>
<td>$44.1K</td>
<td>1.5K</td>
<td>101</td>
</tr>
</tbody>
</table>

<h3>About Capricor Therapeutics</h3>
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
Following our analysis of the options activities associated with Capricor Therapeutics, we pivot to a closer look at the company's own performance.
<h3>Capricor Therapeutics's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,069,496, the price of CAPR is down by -9.18%, reaching $11.97.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 46 days from now.</li>
</ul>
<h3>Expert Opinions on Capricor Therapeutics</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $65.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $77. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $77. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $77. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $30. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Capricor Therapeutics options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Check Out What Whales Are Doing With CAPR

WIIM

Capricor Therapeutics shares are trading higher after the company reported Q4 financial results and beat its EPS and revenue estimates. HC Wainwright & Co. reiterated a Buy on the stock and Cantor Fitzgerald maintained an Overweight rating.

U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Thursday.
Shares of Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and <a href="https://www.benzinga.com/25/03/44417609/jabil-q2-earnings-beat-estimates-amid-cloud-and-data-center-growth-stock-surges-on-upbeat-outlook">raised its FY25 guidance</a>.
Jabil reported second-quarter adjusted earnings per share of $1.94, beating the analyst consensus estimate of $1.83. Quarterly sales of $6.73 billion outpaced the analyst consensus estimate of $6.408 billion.
Jabil shares jumped 5.1% to $146.67 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>ProAssurance Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) shares jumped 47.8% to $22.98 after the company announced it will be acquired by The Doctors Company for $25.00 per share in cash.</li>
<li>ARS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) gained 24.77% to $14.53 following fourth-quarter results.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares rose 19.8% to $2.42.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 19.5% to $36.77.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) rose 13.7% to $13.90 following strong quarterly results.</li>
<li>Titan Machinery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) gained 12.9% to $16.63 following strong quarterly sales.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) gained 9.9% to $193.50 after Piper Sandler upgraded the stock from Neutral to Overweight..</li>
<li>Gambling.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) shares rose 9.4% to $13.65 after reporting upbeat quarterly results.</li>
<li>Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) gained 9% to $31.31.</li>
<li>Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) rose 7.7% to $202.57 after the company issued FY25 sales guidance above estimates.</li>
<li>QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) gained 7.4% to $14.02. On Thursday, QXO disclosed entering into a definitive merger agreement to acquire Beacon for $124.35 per share in cash.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) rose 6.8% to $80.73 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>The Boston Beer Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) gained 4.4% to $228.68. Citigroup analyst Filippo Falorni upgraded Boston Beer from Neutral to Buy and raised the price target from $265 to $280.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/news/earnings/25/03/44415297/how-to-earn-500-a-month-from-micron-technology-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Micron Technology Stock Ahead Of Q2 Earnings</a></li>
</ul>

Intraday Update

CLEU

CVNA

FIVE

GAMB

IMCR

SPRY

TITN

Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight and maintains $30 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Capricor Therapeutics, Maintains $30 Price Target

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Capricor Therapeutics, revealing an average target of $77.0, a high estimate of $77.00, and a low estimate of $77.00. Staying constant with the previous average price target, the current average remains unchanged. 
<img src="https://www.benzinga.com/files/images/story/2025/1742472128_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Capricor Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Capricor Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Capricor Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Capricor Therapeutics</h2>
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
<h3>Capricor Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Capricor Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -63.44% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -555.2%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -31.48%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Capricor Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -19.14%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 38.46 percent. This is a 700 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $11.10 million which beat the analyst consensus estimate of $5.68 million by 95.37 percent. This is a 8.17 percent decrease over sales of $12.09 million the same period last year.

Earnings

Earnings Beats

Capricor Therapeutics Q4 2024 GAAP EPS $(0.16) Beats $(0.26) Estimate, Sales $11.10M Beat $5.68M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Corporacion America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAAP#NYSE">CAAP</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $373.00 million. 
• Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) is likely to report quarterly earnings at $1.19 per share on revenue of $674.52 million. 
• Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $294.60 million. 
• GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $430.70 million. 
• MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) is estimated to report quarterly loss at $0.61 per share on revenue of $5.75 million. 
• Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) is expected to report quarterly earnings at $6.25 per share on revenue of $2.33 billion. 
• J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $142.33 million. 
• Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $4.60 million. 
• Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) is projected to report quarterly loss at $0.11 per share on revenue of $269.59 million. 
• American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is estimated to report earnings for its fourth quarter. 
• Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $747.94 million. 
• Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) is projected to report quarterly earnings at $2.93 per share on revenue of $2.35 billion. 
• General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $4.96 billion. 
• One Stop Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $15.00 million. 
• Direxion Daily CSI China Internet Index Bull 2X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEB#NYSE">CWEB</a>) is estimated to report earnings for its fourth quarter. 
• HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) is expected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) is projected to report quarterly earnings at $3.38 per share on revenue of $1.38 billion. 
• Epsilon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSN#NASDAQ">EPSN</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $7.22 million. 
• Team (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TISI#NYSE">TISI</a>) is likely to report earnings for its fourth quarter. 
• TWFG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWFG#NASDAQ">TWFG</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $47.78 million. 
• Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $1.30 million. 
• SWK Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKH#NASDAQ">SWKH</a>) is expected to report quarterly earnings at $1.01 per share on revenue of $9.70 million. 
• scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) is projected to report quarterly loss at $0.39 per share on revenue of $12.18 million. 
• CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is likely to report earnings for its fourth quarter. 
• Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $8.89 million. 
• JOYY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $559.67 million. 
• Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) is estimated to report quarterly loss at $0.41 per share on revenue of $3.88 million. 
• icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $4.50 million. 
• Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $9.87 million. 
• Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) is projected to report quarterly loss at $0.24 per share on revenue of $15 thousand. 
• LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) is estimated to report earnings for its fourth quarter. 
• North American (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOA#NYSE">NOA</a>) is estimated to report quarterly earnings at $1.17 per share on revenue of $318.60 million. 
• Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) is likely to report quarterly loss at $0.58 per share on revenue of $2.47 million. 
• Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $732.00 million. 
• Prudential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUK#NYSE">PUK</a>) is expected to report earnings for its Fiscal Year 2024. 
• Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $4.94 million. 
• FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) is expected to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEVA

CAAP

CWEB

EPSN

GROY

ICAD

JILL

LENZ

LQDA

MDWD

OLLI

PGEN

PRSO

SCPH

SERA

SRAD

SWKH

TISI

TWFG

Earnings Scheduled For March 19, 2025

--Preservation of Skeletal Muscle Function Shown Over 3 Years Resulting in 52% Slowing of Disease--
--Data Presented at the 2025 Muscular Dystrophy Association (MDA) Conference--

Biotech

General

Capricor Therapeutics Announces Data From Ongoing HOPE-2 Open Label Extension Clinical Trial

&nbsp;NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that acceptance has been received by Capricor Therapeutics, Inc. (Headquarters: California, USA, CEO: Linda Marbán, (Headquarters: California, USA, CEO: Linda Marbán, NASDAQ:<a href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>)&nbsp;from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) filing for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy.&nbsp;The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of August 31, 2025, and at this time, the FDA has not identified any potential review issues.
Nippon Shinyaku and Capricor entered into an exclusive distribution agreement for deramiocel for the U.S. in January 2022. NS Pharma will be exclusively responsible for commercialization and distribution of deramiocel in the U.S.

Capricor Accepted By FDA For Deramiocel BLA Filing For DMD Cardiomyopathy, Priority Review Granted, PDUFA Date Set For August 31, 2025; NS Pharma To Commercialize In U.S.

On Tuesday, the FDA accepted for review Capricor Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) Biologics License Application for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44104490/capricor-therapeutics-announces-fda-acceptance-and-priority-review-of-its-biologics-license-applic" rel="noreferrer noopener">(DMD) cardiomyopathy.</a>
DMD cardiomyopathy is a heart condition characterized by cardiac fibrosis, arrhythmias, and heart failure.&nbsp;
Additionally, the FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of August 31, 2025.
The FDA has not identified any potential review issues.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41294970/capricor-therapeutics-says-duchenne-muscular-dystrophy-candidate-shows-sustained-cardiac-skeletal" rel="noreferrer noopener">Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years</a>
The BLA submission is supported by Capricor&#8217;s existing cardiac data from its Phase 2 HOPE-2 and HOPE-2 Open Label Extension (OLE) trials compared to natural history data.
The FDA also informed the company that they have not yet decided whether an Advisory Committee meeting is needed regarding this application.
Deramiocel for DMD has received&nbsp;Orphan Drug Designation&nbsp;from the FDA and European Medicines Agency.
In addition, if Capricor were to receive FDA marketing approval for deramiocel regarding the treatment of DMD by September 30, 2026, Capricor would be eligible to receive a Priority Review Voucher based on its previous receipt of a rare pediatric disease designation.
Price Action: CAPR stock is up 6.33% at $14.54 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44113171/agentexchange-salesforces-new-ai-marketplace-targets-6-trillion-digital-labor-market" target="_blank" rel="noreferrer noopener">AgentExchange: Salesforce&#8217;s New AI Marketplace Targets $6 Trillion Digital Labor Market</a></li>
</ul>

Health Care

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

CAPR: 20% &#x7C; <a href="https://www.benzinga.com//node/44104968">Capricor Therapeutics shares are trading higher after the FDA accepted and granted priority review for the company's Biologics License Application for Deramiocel to treat Duchenne Muscular Dystrophy.</a>
&nbsp;
WBA: 7% &#x7C; <a href="https://www.benzinga.com//node/44104926">Walgreens Boots Alliance shares are trading higher following a WSJ report suggesting the company is nearing a go-private deal with Sycamore Partners.</a>
&nbsp;
GCT: -20% &#x7C; <a href="https://www.benzinga.com//node/44104955">GigaCloud Tech shares are trading lower after the company issued Q1 sales guidance below estimates.</a>

Market-Moving News for March 4th

Capricor Therapeutics shares are trading higher after the FDA accepted and granted priority review for the company's Biologics License Application for Deramiocel to treat Duchenne Muscular Dystrophy.

If approved, deramiocel would be first therapy to treat Duchenne muscular dystrophy cardiomyopathy. At this time, FDA has not identified any potential review issues with the BLA.

Capricor Says FDA Granted Deramiocel BLA Priority Review And Assigned PDUFA Target Action Date Of August 31, 2025

Additionally, the FDA granted the BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of August 31, 2025 and at this time, the FDA has not identified any potential review issues.

Capricor Says FDA Accepted For Review Its Biologics License Application Seeking Full Approval For Deramiocel For Patients Diagnosed With Duchenne Muscular Dystrophy Cardiomyopathy

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$142.00</td>
<td>$132.6K</td>
<td>236</td>
<td>1.1K</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$35.0K</td>
<td>3.7K</td>
<td>750</td>
</tr>
<tr>
<td>SOLV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$70.00</td>
<td>$25.0K</td>
<td>711</td>
<td>608</td>
</tr>
<tr>
<td>GEHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$92.50</td>
<td>$83.4K</td>
<td>14</td>
<td>340</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$210.00</td>
<td>$87.3K</td>
<td>2.5K</td>
<td>284</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$45.00</td>
<td>$28.6K</td>
<td>53.7K</td>
<td>193</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$110.00</td>
<td>$106.5K</td>
<td>210</td>
<td>101</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$220.00</td>
<td>$64.2K</td>
<td>184</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option trade with neutral sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 829 contract(s) at a $142.00 strike. The total cost received by the writing party (or parties) was $132.6K, with a price of $160.0 per contract. There were 236 open contracts at this strike prior to today, and today 1103 contract(s) were bought and sold. 
• For CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on January 17, 2025. This event was a transfer of 250 contract(s) at a $15.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $140.0 per contract. There were 3727 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding SOLV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $250.0 per contract. There were 711 open contracts at this strike prior to today, and today 608 contract(s) were bought and sold. 
• For GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we notice a call option sweep that happens to be bearish, expiring in 254 day(s) on September 19, 2025. This event was a transfer of 139 contract(s) at a $92.50 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $83.4K, with a price of $600.0 per contract. There were 14 open contracts at this strike prior to today, and today 340 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bullish sentiment. It expires in 373 day(s) on January 16, 2026. Parties traded 148 contract(s) at a $210.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $87.3K, with a price of $590.0 per contract. There were 2546 open contracts at this strike prior to today, and today 284 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option trade that happens to be bullish, expiring in 44 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $28.6K, with a price of $286.0 per contract. There were 53788 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 254 day(s) on September 19, 2025. Parties traded 101 contract(s) at a $110.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1055.0 per contract. There were 210 open contracts at this strike prior to today, and today 101 contract(s) were bought and sold. 
• For VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we notice a call option trade that happens to be neutral, expiring in 373 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $64.2K, with a price of $3210.0 per contract. There were 184 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

GEHC

SOLV

VEEV

8 Health Care Stocks Whale Activity In Today's Session

Press Releases

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics to Participate in Upcoming Investor Conferences

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Comments

Capricor Therapeutics

ニュース

パートナーシップ

ベンジンガ・グローバル